Table 3

Symptom resolution at 4 weeks in trials of esomeprazole compared with another proton pump inhibitor in erosive gastroesophageal reflux disease

StudyPortion of group with resolution of symptoms at 4 weeksRisk difference (95% CI)Pooled estimate
Esomeprazole 40 mg compared with omeprazole 20 mg
Kahrilas 2000565% vs. 57%8% (2 to 13) 8% (3% to 13%) number needed to treat=13
Kao 20031674% vs. 51%23% (3 to 42)
Richter 20011268% vs. 58%10% (6 to 14)
Schmitt 20063665% vs. 63%2% (−4 to 7)
Esomeprazole 40 mg compared with lansoprazole 30 mg
Castell 2002463% vs. 60%3% (0 to 5) 5% (0% to 9%)
Fennerty 200529 (ITTa)69% vs. 61%8% (2 to 14)
Esomeprazole 40 mg compared with pantoprazole 40 mg
Bardhan 20073364% vs. 63%1% (−7 to 9) 0% (−6% to 6%)
Gillessen 20042035% vs. 37%−2% (−16 to 11)
Sholten 20031070% vs. 71%−1% (−13 to 11)
a

Intention-to-treat analysis performed for this report.

From: Results

Cover of Drug Class Review: Proton Pump Inhibitors
Drug Class Review: Proton Pump Inhibitors: Final Report Update 5 [Internet].
McDonagh MS, Carson S, Thakurta S.
Portland (OR): Oregon Health & Science University; 2009 May.
Copyright © 2009, Oregon Health & Science University, Portland, Oregon.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.